Lv6
1628 积分 2024-10-14 加入
ROME trial wasn't built in a day: the decade-long journey to randomized evidence in precision oncology
14天前
已完结
Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study
14天前
已完结
PET/CT-guided management of immune checkpoint blockade and post-treatment multi-modal profiling in long-term responders with metastatic lung cancer in the National Network Genomic Medicine Lung Cancer Germany (nNGM)
14天前
已关闭
Comment on: ALBAN (GETUG-AFU 37): a phase III, randomized, open-label, international trial of intravenous atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) versus BCG alone in BCG-naive high-risk, non-muscle-invasive bladder cancer (NMIBC)
14天前
已完结
A tale of two trials: TAILORx and PlanB. Letter to the Editor regarding ‘Impact of anthracyclines in genomic high-risk, node-negative, HR-positive/HER2-negative breast cancer’ by Chen et al
14天前
已完结
A temporal paradox in the proposed risk-adjusted surveillance algorithm for metastatic colorectal cancer
14天前
已完结
Development and validation of artificial intelligence-assisted volumetric response criteria in pleural mesothelioma (ARTIMES): a retrospective, multicohort, multicentre study
1个月前
已完结
ctDNA-guided adjuvant therapy in stage II colon cancer: a step forward, but not the final word
1个月前
已完结
Efficacy of Perioperative Pembrolizumab in Mismatch Repair Deficient/Microsatellite Unstable Localized Colorectal Cancers: Results of the Phase II Trial IMHOTEP
1个月前
已关闭
Efficacy of Perioperative Pembrolizumab in Mismatch Repair Deficient/Microsatellite Unstable Localized Colorectal Cancers: Results of the Phase II Trial IMHOTEP
1个月前
已完结
皖公网安备34019202002308
